You just read:

Takeda Receives Simultaneous European Marketing Authorization for Three New Type 2 Diabetes Therapies, Vipidia[TM] ▼ (alogliptin) and Fixed-Dose Combinations Vipdomet[TM] ▼ (alogliptin and metformin) and Incresync[TM] ▼ (alogliptin and pioglitazone)

News provided by

Takeda Pharmaceutical Company Limited

24 Sep, 2013, 07:00 BST